Get Premium Access
Info

AnesthesiaExam Podcast

David Rosenblum, MD, creator of AnesthesiaExam.com and ABAstagedExam.com discusses anesthesiology board prep and issues relevant to anesthesiologists.
RSS Feed Premium Podcasts
AnesthesiaExam Podcast
2024
March
February
January


2023
November
October
September
August
July
June
May
April
March
February
January


2022
December
November
October
September
August
July
June
May
April
March
February
January


2021
December
November
October
September
August
July
June
May
April
March
February
January


2020
December
November
October
September
August
July
June
May
April
March
February
January


2019
December
November
October
September
August
July
June
May
April
March
February
January


2018
December
November
October
September
August
July
June
May
April
March
February
January


2017
December
November
October
September
August
July
June
May
April
March
February
January


2016
November
August
July
June
May
April
March
February
January


2015
December
November
October
September
August
July
June
May
April


Categories

All Episodes
Archives
Categories
Premium Episodes
Now displaying: Page 1
Jun 16, 2020

Low Dose Naltrexone for Pain

New Courses at PainExam

Ultrasound Series

Regenerative Spine Pain Course

Regenerative Medicine

Regenerative Medicine Spine Pain Course

 

Dr. Rosenblum Discusses the uses and theory behind Low Dose Naltrexone for Chronic Pain and Inflammation.

References

Debasish Hota, MD, DM, Anand Srinivasan, MD, Pinaki Dutta, MD, DM, Anil Bhansali, MD, DM, Amitava Chakrabarti, MD, DM, Off-Label, Low-Dose Naltrexone for Refractory Painful Diabetic Neuropathy, Pain Medicine, Volume 17, Issue 4, April 2016, Pages 790–791, https://doi.org/10.1093/pm/pnv009

Younger et al: The Use of Low-Dose Naltrexone (LDN) as a Novel Anti-Inflammatory Treatment for Chronic Pain. Clinical Rheumatology (2014) 33:451-459

KTojan, VroomanB.  Low-Dose Naltrexone (LDN) review of Therapeutic Utilization. Med. Sci. 2018, 6,82

 

Subscribe to our mailing list

* indicates required

 

0 Comments
Adding comments is not available at this time.